Mirati Therapeutics, Inc. – NASDAQ:MRTX

Add to watchlist

Market closed

Open in 29 minutes

-0.41%

month

+5.42%

quarter

+28.56%

year

Market Cap	4.11B
Enterprise value	N/A

P/E	-2.99
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	177.16
Price/Book	2.21
PEG ratio	0.17
EPS	-12.06

Revenue	38.19M
EBITDA	-763.76M
Income	-716.64M
Revenue Q/Q	201.97%
Revenue Y/Y	223.62%

Profit margin	-5957.44%
Oper. margin	-6107.98%
Gross margin	2.69%
EBIT margin	-6107.98%
EBITDA margin	-1999.85%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Profit margin
Dec 2022	934K	-202.47M	-21678.27%
Mar 2023	7.16M	-175.34M	-2446.62%
Jun 2023	13.69M	-176.91M	-1292.28%
Sep 2023	16.4M	-161.90M	-987.22%

Mirati Therapeutics Financials Estimate

Q Y

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Analyst Estimates
2025	316.48M	-585.46M	-184.99%

Analysts Price target
Financials & Ratios estimates

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Earnings per share (EPS)
2024-02-27	-2.61	-3.51

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Debt to assets
Dec 2022	1202647000	206.13M	17.14%
Mar 2023	1033761000	171.13M	16.55%
Jun 2023	915043000	186.09M	20.34%
Sep 2023	1129708000	183.24M	16.22%

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Cash Flow
Dec 2022	-128.8M	59.29M	5.92M
Mar 2023	-190.18M	195.15M	1.72M
Jun 2023	-131.4M	15.53M	3.84M
Sep 2023	-143.71M	-62.19M	334.7M

Mirati Therapeutics alternative data

Mirati Therapeutics
Employees

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Employee count
Aug 2023	587
Sep 2023	587
Oct 2023	587
Nov 2023	587
Dec 2023	587
Jan 2024	587
Feb 2024	587
Mar 2024	587
Apr 2024	587
May 2024	587
Jun 2024	587
Jul 2024	587

Mirati Therapeutics
Hedge Funds Holdings Q1 2022

100.00% 0.00%

of MRTX is owned by hedge funds

243 -9

hedge funds hold MRTX stock

57.00M +164.73K

shares is hold by hedge funds

MRTX hedge funds holdings changes

Mirati Therapeutics
Insider Trading

Mirati Therapeutics, Inc. (NASDAQ:MRTX): Insider trades (number of shares)
Period	Buy	Sel
May 2023	0	619
Jun 2023	0	4647
Aug 2023	2528737	0
Sep 2023	0	2388
Dec 2023	0	4607
Jan 2024	0	6815

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Jan 2024	HICKEY BENJAMIN officer: EVP, Chief Commercial Officer officer: EVP, Chief Commercial ..	Common Stock	966	$59.02	$57,013
Sale	16 Jan 2024	HICKEY BENJAMIN officer: EVP, Chief Commercial Officer officer: EVP, Chief Commercial ..	Common Stock	631	$59.02	$37,242
Sale	16 Jan 2024	CHRISTENSEN JAMIE officer: EVP & Chief Scientific Officer officer: EVP & Chief Scientific..	Common Stock	966	$59.02	$57,013
Sale	16 Jan 2024	CHRISTENSEN JAMIE officer: EVP & Chief Scientific Officer officer: EVP & Chief Scientific..	Common Stock	631	$59.02	$37,242
Sale	8 Jan 2024	HICKEY BENJAMIN officer: EVP, Chief Commercial Officer officer: EVP, Chief Commercial ..	Common Stock	2,090	$58.92	$123,143
Sale	4 Jan 2024	CHRISTENSEN JAMIE officer: EVP & Chief Scientific Officer officer: EVP & Chief Scientific..	Common Stock	1,531	$58.81	$90,038
Sale	18 Dec 2023	CHRISTENSEN JAMIE officer: EVP & Chief Scientific Officer officer: EVP & Chief Scientific..	Common Stock	2,387	$57.5	$137,253
Sale	13 Dec 2023	HICKEY BENJAMIN officer: EVP, Chief Commercial Officer officer: EVP, Chief Commercial ..	Common Stock	2,220	$56.67	$125,807
Sale	8 Sep 2023	CHRISTENSEN JAMIE officer: EVP & Chief Scientific Officer officer: EVP & Chief Scientific..	Common Stock	2,388	$35.63	$85,084
Purchase	11 Aug 2023	BOXER CAPITAL, LLC	Common Stock	2,402,880	$27.8	$66,800,064

MRTX insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER Filling date: 3 Jun 2020 Issue date: 1 Sep 2022	3 Jun 2020	1 Sep 2022
Application	Application NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS Filling date: 21 Apr 2020 Issue date: 7 Jul 2022	21 Apr 2020	7 Jul 2022
Application	Application TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Filling date: 16 Dec 2021 Issue date: 23 Jun 2022	16 Dec 2021	23 Jun 2022
Application	Application COMBINATION THERAPIES Filling date: 9 Sep 2019 Issue date: 31 Mar 2022	9 Sep 2019	31 Mar 2022
Application	Application COMBINATION THERAPIES Filling date: 5 Dec 2019 Issue date: 17 Mar 2022	5 Dec 2019	17 Mar 2022
Application	Application COMBINATION THERAPIES Filling date: 10 Sep 2019 Issue date: 24 Feb 2022	10 Sep 2019	24 Feb 2022
Application	Application COMBINATION THERAPIES Filling date: 9 Sep 2019 Issue date: 24 Feb 2022	9 Sep 2019	24 Feb 2022
Application	Application COMBINATION THERAPIES Filling date: 10 Sep 2019 Issue date: 10 Feb 2022	10 Sep 2019	10 Feb 2022
Grant	Grant Utility: Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors Filling date: 31 Mar 2021 Issue date: 11 Jan 2022	31 Mar 2021	11 Jan 2022
Application	Application KRAS G12C INHIBITORS Filling date: 6 May 2019 Issue date: 9 Dec 2021	6 May 2019	9 Dec 2021

Mirati Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 9 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 28 Feb 2023	Q4 2022 Earnings Call Transcript
Q3 2022 8 Nov 2022	Q3 2022 Earnings Call Transcript

MRTX earnings call transcripts

Mirati Therapeutics
Executives

Insider	Age	Compensation
Dr. Charles M. Baum M.D., Ph.D. (1958) Founder, Pres, Head of R&D and Director	67	$1,130,000
Dr. James G. Christensen Ph.D. (1968) Chief Scientific Officer	57	$820,050
Mr. Benjamin J. Hickey M.B.A. (1975) Chief Commercial Officer	50	$798,320

Mirati Therapeutics
Latest News

Friday, 5 April 2024
04:54	How this insider trader nailed every single stock trade	Finbold
Thursday, 11 January 2024
10:33	Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC	Zacks Investment Research
Wednesday, 6 December 2023
12:47	Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?	Zacks Investment Research
Friday, 10 November 2023
09:02	Mirati's lung cancer drug gets EU's regulatory backing	Reuters
Tuesday, 7 November 2023
09:01	Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations	Zacks Investment Research
Sunday, 22 October 2023
08:53	Bristol-Myers Squibb Acquisition Of Mirati Makes Sense	Seeking Alpha
Tuesday, 10 October 2023
12:47	Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus	Zacks Investment Research
Monday, 9 October 2023
17:16	Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal	CNBC Television
17:13	Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma	Yahoo Finance
15:03	Analysts Target Biotech Name on Buyout Buzz	Schaeffers Research
13:04	Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics	Invezz
12:05	Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio	Investopedia
11:40	Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal	Fox Business
10:48	Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B	Yahoo Finance
05:27	Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion	Barrons
Sunday, 8 October 2023
19:34	Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion	Market Watch
17:56	Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal	Reuters
Friday, 6 October 2023
12:47	Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout	Zacks Investment Research
Wednesday, 27 September 2023
16:30	Mirati To Present Updated Clinical Data at ESMO Congress 2023	PRNewsWire
Friday, 22 September 2023
06:01	Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?	Zacks Investment Research
Monday, 21 August 2023
16:00	Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer	PRNewsWire
Saturday, 19 August 2023
07:40	3 Under-the-Radar Biotech Stocks to Buy in 2023	The Motley Fool
Wednesday, 9 August 2023
11:27	Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales	Zacks Investment Research
10:56	Why Shares of Mirati Therapeutics Are Jumping Wednesday	The Motley Fool
Tuesday, 8 August 2023
20:51	Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript	Seeking Alpha
19:41	Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates	Zacks Investment Research
Tuesday, 25 July 2023
16:30	Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023	PRNewsWire
Monday, 24 July 2023
13:05	Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing	Zacks Investment Research
Friday, 21 July 2023
08:06	Mirati Therapeutics shares fall after lung cancer drug gets negative opinion from European regulators	Market Watch
06:22	EU regulator declines to back Mirati's lung cancer drug	Reuters

Ideas & Opinions

Seeking Alpha 31 Dec 2023

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Seeking Alpha 12 Nov 2023

Verastem: Potential Accelerated Approval Filing In H1 2024
Seeking Alpha 23 Oct 2023

Circling Bank On Tango Therapeutics
Seeking Alpha 28 Aug 2023

Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
Seeking Alpha 10 Aug 2023

Tango Stock Surges On Peer Data Merits Excitement And Perspective
Seeking Alpha 20 Mar 2023

Mirati's Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market
Seeking Alpha 8 Feb 2023

Mirati Therapeutics: Suddenly A Battleground Stock
Seeking Alpha 13 Dec 2022

Zai Labs: Biopharma's Alibaba, But Better
Seeking Alpha 15 Sep 2022

Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer
Seeking Alpha 8 Sep 2022

Mirati: A Potential Blockbuster Stock, Will Need Patience

Frequently Asked Questions (FAQ)

When is Mirati Therapeutics's next earnings date?

Unfortunately, Mirati Therapeutics's (MRTX) next earnings date is currently unknown.
Does Mirati Therapeutics pay dividends?

No, Mirati Therapeutics does not pay dividends.
How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of 4.11B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 82.75% to 12.44M US dollars. Mirati Therapeutics made a loss 740.87M US dollars in net income (profit) last year or -$3.51 on an earnings per share basis.
What is Mirati Therapeutics's stock symbol?

Mirati Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "MRTX".
What is Mirati Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Mirati Therapeutics?

Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Mirati Therapeutics's key executives?
Mirati Therapeutics's management team includes the following people:
- Dr. Charles M. Baum M.D., Ph.D. Founder, Pres, Head of R&D and Director(age: 67, pay: $1,130,000)
- Dr. James G. Christensen Ph.D. Chief Scientific Officer(age: 57, pay: $820,050)
- Mr. Benjamin J. Hickey M.B.A. Chief Commercial Officer(age: 50, pay: $798,320)
Is Mirati Therapeutics founder-led company?

Yes, Mirati Therapeutics is a company led by its founder Dr. Charles M. Baum M.D., Ph.D..
How many employees does Mirati Therapeutics have?

As Jul 2024, Mirati Therapeutics employs 587 workers.
When Mirati Therapeutics went public?

Mirati Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 15 Jul 2013.
What is Mirati Therapeutics's official website?

The official website for Mirati Therapeutics is mirati.com.
Where are Mirati Therapeutics's headquarters?

Mirati Therapeutics is headquartered at 3545 Cray Court, San Diego, CA.
How can i contact Mirati Therapeutics?

Mirati Therapeutics's mailing address is 3545 Cray Court, San Diego, CA and company can be reached via phone at 858 332 3410.

Mirati Therapeutics, Inc.

mirati.com

Exchange:

NASDAQ

Full time employees:

587

Industry:

Biotechnology

Sector:

Healthcare

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

858 332 3410

3545 Cray Court
San Diego, CA 92121

CIK: 0001576263
ISIN: US60468T1051
CUSIP: 60468T105